Dameshek W, Necheles T, Finkle H, Allen D (1965) Therapy of Acute Leukemia, 1965. Blood 26(2):220

Article  CAS  Google Scholar 

Sitki Copur M, Harrold L, Chu E (2021) Common Chemotherapy Regimens in Clinical Practice. In: Chu E, DeVita VT Physicians' Cancer Chemotherapy Drug Manual 2020. In: Jones and Bartlett Publishers I (ed). Boston, USA,

Department of Health and Human Services FDA (2013) Codevelopment of two or more new investigational drugs for use in combination. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf. Accessed 8 July 2018

Administration USFaD (2016–2019) Hematology/Oncology (Cancer) Approvals & Safety Notifications. https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Accessed January 5, 2020

Centerwatch FDA approved drugs for oncology. http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology. Accessed 2 January, 2020

Administration USFaD Drugs@FDA: FDA approved drug products. . http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 2 January, 2020

Department of Health and Human Services FaDA Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed July 18, 2018

Nottage M, Siu LL (2002) Principles of clinical trial design. J Clin Oncol 20(18 Suppl):42S-46S

PubMed  Google Scholar 

Lexchin J, Graham J, Herder M, Jefferson T, Lemmens T (2021) Regulators, pivotal clinical trials, and drug regulation in the age of COVID-19. Int J Health Serv 51(1):5–13. https://doi.org/10.1177/0020731420979824

Article  PubMed  Google Scholar 

Lu D, Lu T, Stroh M, Graham RA, Agarwal P, Musib L, Li CC, Lum BL, Joshi A (2016) A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. Cancer Chemother Pharmacol 77(3):459–476. https://doi.org/10.1007/s00280-015-2931-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mirza M, Avall-Lundqvist E, Birrer M (2019) Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: a randomized controlled chemotherapy-free study — NSGOAVANOVA2/ENGOT-OV24. J Clin Oncol 37:Suppl: 5505

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK (2018) Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 36(9):859–866. https://doi.org/10.1200/JCO.2017.75.5207

Article  PubMed  PubMed Central  CAS  Google Scholar 

Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD (2015) Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 33(31):3635–3640. https://doi.org/10.1200/JCO.2014.59.9258

Article  PubMed  PubMed Central  CAS  Google Scholar 

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630–2637. https://doi.org/10.1200/JCO.2008.18.8391

Article  PubMed  CAS  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. https://doi.org/10.1016/S1470-2045(14)71159-3

Article  PubMed  CAS  Google Scholar 

Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC (2008) Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol 26(2):190–195. https://doi.org/10.1200/JCO.2007.12.7712

Article  PubMed  Google Scholar 

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703. https://doi.org/10.1056/NEJMoa1210093

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tabernero J, Geel RV, Guren TK, Yaeger RD, Spreafico A, Faris JE, Yoshino T, Yamada Y, Kim TW, Bendell JC, Schuler MH, Lenz H, Eskens F, Desai J, Hochster HS, Avsar E, Demuth T, Sandor V, Elez E, Schellens JHM (2016) Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J Clin Oncol 34(15_suppl):3544–3544. https://doi.org/10.1200/JCO.2016.34.15_suppl.3544

Article  Google Scholar 

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36(26):2684–2692. https://doi.org/10.1200/JCO.2017.77.6112

Article  PubMed  PubMed Central  CAS  Google Scholar 

Garcia-Manero J, McCloskey J, Griffiths EA (2019) Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Blood 134(Supplement_1):846. https://doi.org/10.1182/blood-2019-122980

Article  Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603–615. https://doi.org/10.1016/S1470-2045(18)30142-6

Article  PubMed  CAS  Google Scholar 

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381(8):727–738. https://doi.org/10.1056/NEJMoa1903455

Article  PubMed  CAS  Google Scholar 

Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21(7):978–988. https://doi.org/10.1016/S1470-2045(20)30225-4

Article  PubMed  CAS  Google Scholar 

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S (2017) Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 130(8):974–981. https://doi.org/10.1182/blood-2017-05-785246

Article  PubMed  PubMed Central  CAS  Google Scholar 

Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A (2020) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38(26):2981–2992. https://doi.org/10.1200/JCO.19.02627

Article  PubMed  PubMed Central  Google Scholar 

Administration USFaD (2015) FARYDAK® (panobinostat) clinical pharmacology and biopharmaceutics review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000TOC.cfm. Accessed October 16, 2021

(CHMP) CfMPfHU (2019) Tecentriq: EPAR - assessment report - variation

Bailly C, Thuru X, Quesnel B (2020) Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. https://doi.org/10.1093/narcan/zcaa002

Article  PubMed  PubMed Central  Google Scholar 

Hungria VTM, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, Arrais C, Avendaño-Flores O, Barroso F, Basquiera AL, Cao C, Cugliari MS, Enrico A, Foggliatto LM, Galvez KM, Gomez D, Gomez A, de Iracema D, Farias D, Lopez L, Mantilla WA, Martínez D, Mela MJ, Miguel CE, Ovilla R, Palmer L, Pavlovsky C, Ramos C, Remaggi G, Santucci R, Schusterschitz S, Sossa CL, Tuna-Aguilar E, Vela J, Santos T, de la Mora O, Machnicki G, Fernandez M, Barreyro P (2019) Epidemiology of hematologic malignancies in real-world settings: findings from the hemato-oncology latin america observational registry study. J Glob Oncol 5:1–19. https://doi.org/10.1200/jgo.19.00025

Article  Google Scholar 

Bullock JM, Rahman A, Liu Q (2016) Lessons learned: dose selection of small molecule-targeted oncology drugs. Clin Cancer Res 22(11):2630–2638. https://doi.org/10.1158/1078-0432.CCR-15-2646

Article  PubMed  CAS  Google Scholar 

Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS (2014) Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res 20(2):281–288. https://doi.org/10.1158/1078-0432.CCR-13-2103

Article  PubMed  CAS  Google Scholar 

Oncology Center of Excellence, Food and Drug Administration (2022) Project Optimus: Reforming the dose optimization and dose selection paradigm in oncology. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus. Accessed July 21, 2022

Iasonos A, O’Quigley J (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 32(23):2505–2511. https://doi.org/10.1200/JCO.2013.54.6051

Article  PubMed  PubMed Central  Google Scholar 

Riviere MK, Le Tourneau C, Paoletti X, Dubois F, Zohar S (2015) Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Annals Oncol 26(4):669–674. https://doi.org/10.1093/annonc/mdu516

Article  Google Scholar 

Wages NA, Ivanova A, Marchenko O (2016) Practical designs for Phase I combination studies in oncology. J Biopharm Stat 26(1):150–166. https://doi.org/10.1080/10543406.2015.1092029

Article  PubMed  PubMed Central  Google Scholar 

Dumortier T, Looby M, Luttringer O, Heimann G, Klupp J, Junge G, Witte S, VanValen R, Stanski D (2015) Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: a model-based approach. Clin Pharmacol Ther 97(4):411–418. https://doi.org/10.1002/cpt.63

Article  PubMed  CAS  Google Scholar 

Zhao L, Hongshan L, Marathe A, Yu J, Rekić D, Mehrotra N, Sinha V, Wang Y (2016) New advancements in exposure-response analysis to inform regulatory decision making. In: Bonate PL, Howrad DR (eds) Pharmacokinetics in drug development. Springer International, Cham. https://doi.org/10.1007/978-3-319-39053-6_13

Wu K, House L, Ramirez J, Seminerio MJ, Ratain MJ (2013) Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. Clin Cancer Res 19(21):6039–6043. https://doi.org/10.1158/1078-0432.CCR-13-0597

Article  PubMed  CAS  Google Scholar